Publication at Third Faculty of Medicine |
2018
Abstract
Breast-conserving treatment is in most cases the standard therapeutic approach for ductal carcinoma in situ. Adjuvant radiotherapy is a part of this approach, based on the data from randomised studies, lowering the risk of local recurrence and the occurrence of same side invasive carcinomas.
There exist however groups of patients with a very low risk of recidives, which is why it is possible to skip radiotherapy. Their precise identification and definition is however still a matter of research.
Another possible de-escalation approach is shortening the duration of adjuvant therapy and the use of modern techniques in radiotherapy.